Evidence map›Paper›PMID 35744621›Full record

ReviewMicroorganisms2022

Clinical

Victoria Ballén, Virginio Cepas, Carlos Ratia, Yaiza Gabasa, Sara M Soto

Abstract readReview
In one paragraph

Review in Microorganisms, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed.

  1. Escherichia coli bacteriophage vB_EcoS_MS2 effectively prevents biofilm formation but shows limited activity against mature biofilms.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Longitudinal genomic insights into resistance and virulence dynamics of Klebsiella pneumoniae clinical isolates from Pakistan.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026
    Article
  15. Review
  16. Article
  17. Impact of NbACS omega · 2026
    Article
  18. Article
  19. Article
  20. Article

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Victoria BallénISGlobal, Hospital Clínic, Universitat de Barcelona, 08036 Barcelona, Spain.ORCID 0000-0003-1089-600X
Virginio CepasISGlobal, Hospital Clínic, Universitat de Barcelona, 08036 Barcelona, Spain.
Carlos RatiaISGlobal, Hospital Clínic, Universitat de Barcelona, 08036 Barcelona, Spain.ORCID 0000-0001-9030-0717
Yaiza GabasaISGlobal, Hospital Clínic, Universitat de Barcelona, 08036 Barcelona, Spain.
Sara M SotoISGlobal, Hospital Clínic, Universitat de Barcelona, 08036 Barcelona, Spain.ORCID 0000-0002-9507-105X

Funding

European Development Regional Fund "A way to achieve Europe" and operative program Intel-ligent Growth 2014-2020Instituto de Salud Carlos III PI19/00478Ministerio de Ciencia, Tecnología e Innovación (Colombia) COLCIENCIAS Scholarship program N. 756Spanish Network for Research in Infectious Diseases from the Instituto de Salud Carlos III together with the European Development Regional Funds REIPI RD12/0015/0013Spanish Network for Research in Infectious Diseases from the Instituto de Salud Carlos III together with the European Development Regional Funds REIPI RD16/0016/0010
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

biofilmsclinical importanceEscherichia colinon-traditional approachesresistance

Identifiers

PMID35744621
PMCPMC9229135

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.